Statement: Disclosure of Payments
Ottawa, September 27, 2017
The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick:
“The innovative pharmaceutical industry will review any proposed legislation with respect to disclosure of payments once it is tabled.
Innovative Medicines Canada put forward a self-regulatory voluntary framework on disclosure of payments in June 2014.
We would like to work with the government and other stakeholders on the development of these new regulations, with a view to ensuring that they advance patient care, are practical, and are not excessively costly or burdensome for an already strained healthcare system.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information: